Q J Med 2001; 94: 255-260
© 2001 Association of Physicians
Insulin lispro and regular insulin in pregnancy
From the Departments of Medicine (Division of Diabetes) and Obstetrics, Preston Acute Hospital NHS Trust, Preston, UK
Received 19 September 2000 and in revised form 16 March 2001
We assessed the safety of insulin lispro in gestational, type 1 and type 2 diabetes mellitus, analysing 635 pregnancies over a period of 7 years. We also evaluated patient satisfaction, sending an internationally-accepted anonymous diabetes treatment satisfaction questionnaire to 22 patients (three type 1, 19 gestational diabetes) who received regular and lispro insulin in successve pregnancies. The success rate of pregnancies in women with gestational diabetes managed with diet alone (n=325) was 99.3%. All 213 pregnancies in women with gestational diabetes requiring insulin were successful. There was no difference in maternal or fetal outcomes whether patients used regular insulin (n=138) or insulin lispro (n=75), but pre-delivery HbA1c was lower with insulin lispro (p<0.05). Pregnancy loss in patients with pre-gestational diabetes (89 pregnancies in type 1 and eight in type 2 diabetes) was 18.6% for insulin and 3.7% for insulin lispro (p=0.10). The incidences of congenital anomalies with regular insulin were 7.9% and 15.8% in gestational and pre-gestational diabetes, respectively; the figures for insulin lispro were 6.6% (p=0.79) and 3.8% ( p=0.16), respectively. Nineteen of the 22 surveyed patients completed the questionnaire. Satisfaction was higher with insulin lispro (26.3±2.3 vs. 18±8.9, p=0.0005). We found no increase in adverse outcome using lispro insulin in diabetic pregnancies, in either gestational or pre-gestational diabetes. Patient satisfaction favoured insulin lispro. Several patients with type 1 diabetes who used regular insulin during pregnancy, chose lispro after delivery, but all who used lispro in pregnancy preferred to continue.
Address correspondence to Dr A. Bhattacharyya, 214 Plat Lane, Fallowfield, Manchester M14 7BS, UK. e-mail: arpandev{at}aol.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Jovanovic Point: Oral Hypoglycemic Agents Should Not Be Used to Treat Diabetic Pregnant Women Diabetes Care, November 1, 2007; 30(11): 2976 - 2979. [Full Text] [PDF]
|
|
|
|
|
|
L. Jovanovic and D. J. Pettitt Treatment With Insulin and Its Analogs in Pregnancies Complicated by Diabetes Diabetes Care, July 1, 2007; 30(Supplement_2): S220 - S224. [Full Text] [PDF]
|
|
|
|
|
|
M. Dolci, M. Mori, and F. Baccetti Use of Glargine Insulin Before and During Pregnancy in a Woman With Type 1 Diabetes and Addison's Disease Diabetes Care, August 1, 2005; 28(8): 2084 - 2085. [Full Text] [PDF]
|
|
|
|
 |
|
 I. B. Hirsch Insulin Analogues N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ahmad Review: Pharmacology of insulin The British Journal of Diabetes & Vascular Disease, January 1, 2004; 4(1): 10 - 14. [Abstract] [PDF]
|
|